Leerink Partnrs Reaffirms Outperform Rating for XOMA (NASDAQ:XOMA)

Leerink Partnrs reiterated their outperform rating on shares of XOMA (NASDAQ:XOMA - Free Report) in a research note released on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for XOMA's Q1 2024 earnings at ($0.85) EPS, Q2 2024 earnings at ($0.79) EPS, Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.69) EPS, FY2024 earnings at ($2.87) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at $1.05 EPS and FY2028 earnings at $3.31 EPS.

XOMA has been the subject of a number of other research reports. SVB Leerink began coverage on shares of XOMA in a research report on Monday. They issued an outperform rating and a $40.00 target price for the company. HC Wainwright reiterated a buy rating and issued a $74.00 price objective on shares of XOMA in a report on Wednesday.

XOMA Stock Performance

XOMA stock traded down $0.38 during midday trading on Monday, reaching $25.44. 13,491 shares of the stock traded hands, compared to its average volume of 20,276. XOMA has a fifty-two week low of $13.48 and a fifty-two week high of $27.00. The company has a current ratio of 8.68, a quick ratio of 8.68 and a debt-to-equity ratio of 1.34. The firm has a market cap of $296.12 million, a price-to-earnings ratio of -6.39 and a beta of 0.57. The firm has a fifty day moving average price of $25.06 and a two-hundred day moving average price of $20.68.

XOMA (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.13). The business had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.01 million. XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. On average, equities research analysts forecast that XOMA will post -1.73 earnings per share for the current year.

Hedge Funds Weigh In On XOMA

A hedge fund recently raised its stake in XOMA stock. Stonepine Capital Management LLC boosted its holdings in shares of XOMA Co. (NASDAQ:XOMA - Free Report) by 25.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 436,602 shares of the biotechnology company's stock after acquiring an additional 87,203 shares during the quarter. XOMA makes up approximately 2.0% of Stonepine Capital Management LLC's portfolio, making the stock its 12th largest holding. Stonepine Capital Management LLC owned 3.80% of XOMA worth $6,152,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.